You are here
C2N DIAGNOSTICS LLC
http://www.c2ndiagnostics.com
UEI: TE1NNNXJQCD7
# of Employees: 10
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Coverage for costs associated with reading of amyloid PET images from PARIS study
Amount: $1,747,922.00PROJECT SUMMARY FOR PARENT AWARD For a long time, the study of Alzheimer’s disease (AD) in humans has been hampered by the fact that absolute AD diagnosis could only be ascertained by assessment of ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosis
Amount: $224,256.00PROJECT SUMMARY ABSTRACT For a long timethe study of Alzheimer s diseaseADin humans has been hampered by the fact that absolute AD diagnosis could only be ascertained by assessment of brain pathology ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Development of novel assays for measuring concentration and metabolism of Tau in
Amount: $161,927.00DESCRIPTION (provided by applicant): Recently, Drs. Randall Bateman and David Holtzman at the Washington University School of Medicine developed a novel stable isotope labeling kinetics (SILK) methodo ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Measuring metabolism of C-terminal fragments of amyloid beta in the human central
Amount: $814,440.00DESCRIPTION (provided by applicant): This grant will seek to develop a methodology that will allow us to test whether a promising new class of drugs for Alzheimer's disease is having the desired ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health -
Measuring metabolism of C-terminal fragments of amyloid beta in the human central
Amount: $133,098.00DESCRIPTION (provided by applicant): This grant will seek to develop a methodology that will allow us to test whether a promising new class of drugs for Alzheimer's disease is having the desired effec ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health